- Home
- ESGRO vs CGEN Comparison
ESGRO vs CGEN Comparison
Compare ESGRO & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGRO
- CGEN
- Stock Information
- Founded
- ESGRO N/A
- CGEN 1993
- Country
- ESGRO Bermuda
- CGEN Israel
- Employees
- ESGRO 805
- CGEN N/A
- Industry
- ESGRO Property-Casualty Insurers
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESGRO Finance
- CGEN Health Care
- Exchange
- ESGRO Nasdaq
- CGEN Nasdaq
- Market Cap
- ESGRO N/A
- CGEN 134.3M
- IPO Year
- ESGRO N/A
- CGEN 2000
- Fundamental
- Price
- ESGRO $20.49
- CGEN $1.65
- Analyst Decision
- ESGRO
- CGEN Strong Buy
- Analyst Count
- ESGRO 0
- CGEN 1
- Target Price
- ESGRO N/A
- CGEN $4.00
- AVG Volume (30 Days)
- ESGRO N/A
- CGEN 470.1K
- Earning Date
- ESGRO N/A
- CGEN 11-12-2024
- Dividend Yield
- ESGRO N/A
- CGEN N/A
- EPS Growth
- ESGRO N/A
- CGEN N/A
- EPS
- ESGRO N/A
- CGEN 0.02
- Revenue
- ESGRO N/A
- CGEN $59,852,000.00
- Revenue This Year
- ESGRO N/A
- CGEN $57.27
- Revenue Next Year
- ESGRO N/A
- CGEN N/A
- P/E Ratio
- ESGRO N/A
- CGEN $85.40
- Revenue Growth
- ESGRO N/A
- CGEN 698.03
- 52 Week Low
- ESGRO N/A
- CGEN $1.35
- 52 Week High
- ESGRO N/A
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- ESGRO 55.82
- CGEN 56.57
- Support Level
- ESGRO $19.45
- CGEN $1.47
- Resistance Level
- ESGRO $20.66
- CGEN $1.65
- Average True Range (ATR)
- ESGRO 0.39
- CGEN 0.10
- MACD
- ESGRO 0.05
- CGEN 0.00
- Stochastic Oscillator
- ESGRO 85.95
- CGEN 80.80
About ESGRO Enstar Group Limited Depository
Enstar Group Ltd is a (re)insurance group that offers capital release solutions through its network of group companies. It seeks to create value by managing (re)insurance companies and portfolios of (re)insurance and other liability businesses in run-off and striving to generate an attractive risk-adjusted return from its investment portfolio. Its operations are through four reportable segments: Run-off, Assumed Life, Investments, and Legacy Underwriting.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.